C 
16.00
+1.39%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Consun Pharmaceutical Group
Its shares trade on HKEX under the ticker 1681.HK. It has been listed since 19 December 2013. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.98bn and net income of CN¥1.26bn. At that date it held total assets of CN¥7.47bn and shareholders' equity of CN¥5.28bn.
Consun Pharmaceutical Group Ltd. is an investment holding company, which engages in the manufacturing and sales of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2013-12-19. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Dec 2013
- Employees
- 2,649
- Website
- chinaconsun.com ↗
Leadership
Pay as last reported
- Mr. Meng AnExecutive Chairman of the Board and Chief Executive Officer, since 2021CN¥13.8m
- Mr. Peicheng FangVice President
- Mr. Yuk Chuen YoungExecutive Director, since 2025
- Ms. Lanfen FangVice President - Guangzhou Consun
- Mr. Haien GaoBoard Secretary, since 2020
- Mr. Shangwen ZhouDirector, Vice President - Guangzhou Consun
- Dr. Lihua ZhangNon-Executive Director
- Prof. Quan ZhuNon-Executive Director, since 2012CN¥1.1m
- Mr. Weiwu DuanIndependent Non-Executive Director
- Mr. Zhongshi FengIndependent Non-Executive DirectorCN¥144,000
- Dr. Yikai LiIndependent Non-Executive Director
- Mr. Zhuoguang LiIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Consun Pharmaceutical Group Ltd possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong portfolio of high-quality and innovative pharmaceutical products. This enables Consun to meet the diverse healthcare needs of its customers effectively. Secondly, Consun has established a robust distribution network, allowing the company to reach a wide customer base. This network ensures efficient delivery of its products to various regions, enhancing customer satisfaction and market reach. Additionally, Consun enjoys a favorable reputation and brand recognition in the industry, earned through its commitment to quality, reliability, and customer-centric approach. This positive perception enables the company to attract and retain loyal customers, giving it an edge over competitors. Lastly, Consun benefits from a talented and experienced workforce. The company's skilled employees contribute to its effective research and development efforts, as well as the production and marketing of innovative pharmaceutical solutions.
Weaknesses
- Despite its strengths, Consun Pharmaceutical Group Ltd faces certain weaknesses that pose challenges to its growth and market position. One notable weakness is the company's limited presence in international markets. This restricts its expansion opportunities and makes Consun vulnerable to changes in the domestic market. Furthermore, Consun may potentially face issues related to regulatory compliance. The pharmaceutical industry is subject to strict regulations and quality control standards, which can impact Consun's operations and product development processes. Ensuring full compliance can be resource-intensive and time-consuming. Another weakness lies in the company's heavy reliance on a few key products for a significant portion of its revenue. Any decline in the demand or popularity of these products could adversely affect Consun's financial performance and overall competitiveness. Lastly, Consun may possess limited brand recognition outside of its core customer base. This could hinder its ability to expand into new markets and compete effectively with established international players.
Opportunities
- Consun Pharmaceutical Group Ltd has several opportunities to capitalize on and drive its future growth. Firstly, the emerging markets present significant growth prospects for the pharmaceutical industry. Consun can strategically expand its presence in these markets, tapping into the rising demand for healthcare products and services. Moreover, advancements in technology and digitalization offer opportunities for Consun to enhance its operations and customer engagement. By adopting digital platforms and investing in e-commerce capabilities, the company can improve its reach, accessibility, and customer convenience, gaining a competitive edge. Additionally, increasing awareness and demand for natural and herbal products provide Consun a chance to diversify its product offerings. By investing in research and development in this area, the company can cater to the evolving preferences of health-conscious consumers and expand its market share. Furthermore, partnerships and collaborations with other pharmaceutical companies, research institutions, or healthcare providers can enable Consun to access new resources, technologies, and markets. Such collaborations can foster innovation, accelerate product development, and generate new revenue streams.
Threats
- Consun Pharmaceutical Group Ltd faces several threats that may impact its operations and market position. Firstly, intense competition within the pharmaceutical industry poses a threat to Consun's market share and profitability. Competitors may offer similar products, competitive pricing, or aggressive marketing strategies, challenging Consun's market dominance. Secondly, regulatory changes or stricter regulations in the healthcare industry can disrupt Consun's operations and increase compliance costs. These regulatory challenges may also delay product approvals and limit the company's ability to launch new products in a timely manner. Furthermore, patent expirations of key products pose a threat to Consun's revenue and market position. Once a product's patent expires, generic alternatives can enter the market and erode Consun's market share and pricing power. Lastly, unforeseen events like natural disasters or global economic downturns can disrupt Consun's supply chain, manufacturing operations, and demand for pharmaceutical products. Such disruptions can adversely affect the company's financial performance and stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.